SCHEMBL26315807

SCHEMBL26315807

C#CCNC(=O)CCCCCCCCCCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
MAPT P10636 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
EPHX2 P34913 3/20 0.49
TSHR P16473 5/20 0.48
LMNA P02545 1/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
ADRA1A P35348 1/20 0.47
PRMT1 Q99873 1/20 0.45
PPARG P37231 6/20 0.45
PPARD Q03181 6/20 0.45
PPARA Q07869 6/20 0.45
GPR84 Q9NQS5 5/20 0.45
HDAC11 Q96DB2 5/20 0.45
ALDH1A1 P00352 2/20 0.45
TLR2 O60603 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2548314 0.94 CYP1A2 (0.47) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL10021727 0.92 FAAH (0.50) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL26315776 0.91 EPHX2 (0.57) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL3494897 0.85 PHF8 (0.46) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL19521439 0.84 FAAH (0.64) EPHX2MEN1KMT2A
SCHEMBL7105382 0.84 FAAH (0.64) EPHX2MEN1KMT2A
SCHEMBL7113945 0.84 FAAH (0.64) EPHX2MEN1KMT2A
SCHEMBL10226131 0.84 FAAH (0.64) EPHX2MEN1KMT2A
SCHEMBL25542963 0.84 FAAH (0.64) EPHX2MEN1KMT2A
SCHEMBL4565622 0.84 FAAH (0.64) EPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ASGR1, HAVCR2, SLC10A1 HSD17B10 2165/4885CYP1A2 2665/4885CYP2D6 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.